Joseph G Skeate, Emily J Pomeroy, Nicholas J Slipek, Bryan J Jones, Bryce J Wick, Jae-Woong Chang, Walker S Lahr, Erin M Stelljes, Xiaobai Patrinostro, Blake Barnes, Trevor Zarecki, Joshua B Krueger, Jacob E Bridge, Gabrielle M Robbins, Madeline D McCormick, John R Leerar, Kari T Wenzel, Kathlyn M Hornberger, Kirsti Walker, Dalton Smedley, David A Largaespada, Neil Otto, Beau R Webber, Branden S Moriarity
Cellular therapies for the treatment of human diseases, such as chimeric antigen receptor (CAR) T and NK cells have shown remarkable clinical efficacy in treating hematological malignancies, however current methods mainly utilize viral vectors which are limited by their cargo size capacities, high cost, and long timelines for production of clinical reagent. Delivery of genetic cargo via DNA transposon engineering is a more timely and cost-effective approach, yet has been held back by less efficient integration rates...
April 15, 2024: Molecular Therapy